News
AMPH
--
0.00%
--
Bet on These 3 Low-Beta Stocks to Combat Market Volatility
Zacks.com · 16h ago
Amphastar Pharmaceuticals to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / November 22, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate Communications, Tony Marrs, Sr. V.P Regulatory Affairs...
AccessWire · 11/22 11:00
Here's What Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Shareholder Ownership Structure Looks Like
The big shareholder groups in Amphastar Pharmaceuticals, Inc. ( NASDAQ:AMPH ) have power over the company. Generally...
Simply Wall St. · 11/20 11:19
CFO Of Amphastar Pharmaceuticals Trades $325K In Company Stock
William J Peters, CFO at Amphastar Pharmaceuticals (NASDAQ:AMPH), made a large buy and sell of company shares on November 11, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission states that William...
Benzinga · 11/15 16:47
Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / November 11, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate Communications, Tony Marrs, Sr. V.P Regulatory Affairs...
AccessWire · 11/11 21:05
Amphastar Pharmaceuticals Files for Up to $250 Million Mixed-Securities Shelf
MT Newswires · 11/10 03:31
BRIEF-Amphastar Pharmaceuticals Files For Mixed Shelf Of Upto $250 Mln
reuters.com · 11/09 22:34
Amphastar Pharmaceuticals (AMPH) Q3 Earnings and Revenues Beat Estimates
Amphastar (AMPH) delivered earnings and revenue surprises of 109.09% and 8.93%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/08 23:35
BRIEF-Amphastar Pharmaceuticals Posts Q3 EPS Of $0.59
reuters.com · 11/08 23:01
Amphastar Pharmaceuticals: Q3 Earnings Insights
Amphastar Pharmaceuticals (NASDAQ:AMPH) reported its Q3 earnings results on Monday, November 8, 2021 at 04:00 PM. Here's what investors need to know about the announcement.
Benzinga · 11/08 22:46
Amphastar Pharmaceuticals EPS beats by $0.23, beats on revenue
Amphastar Pharmaceuticals (NASDAQ:AMPH): Q3 Non-GAAP EPS of $0.46 beats by $0.23; GAAP EPS of $0.59. Revenue of $112.19M (+34.5% Y/Y) beats by $9.39M. Press Release
Seekingalpha · 11/08 21:54
Amphastar Pharmaceuticals Q3 EPS $0.46 Beats $0.24 Estimate, Sales $112.20M Beat $103.24M Estimate
Amphastar Pharmaceuticals (NASDAQ:AMPH) reported quarterly earnings of $0.46 per share which beat the analyst consensus estimate of $0.24 by 91.67 percent. This is a 206.67 percent increase over earnings of $0.15 per
Benzinga · 11/08 21:31
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2021
2 Million for the Three Months Ended September 30, 2021RANCHO CUCAMONGA, CA / ACCESSWIRE / November 8, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended September 30, 2021.
ACCESSWIRE · 11/08 21:24
Amphastar Pharmaceuticals Tops Street View on Higher Q3 Earnings, Revenue
MT Newswires · 11/08 17:28
-- Earnings Flash (AMPH) AMPHASTAR PHARMACEUTICALS Posts Q3 Revenue $112.2M, vs. Street Est of $102.8M
MT Newswires · 11/08 16:37
Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Well Worth Watching
It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...
Simply Wall St. · 10/20 10:06
Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
With its stock down 7.7% over the past three months, it is easy to disregard Amphastar Pharmaceuticals (NASDAQ:AMPH...
Simply Wall St. · 09/14 10:30
Amphastar Pharmaceuticals to Present at the Wells Fargo 2021 Virtual Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / September 2, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate Communications, Tony Marrs, Sr. V.P Regulatory Affairs and Clinic...
ACCESSWIRE · 09/02 20:05
Insider Trends: Insider Disposition Eases Back 90-Day Buy Trend at Amphastar Pharmaceuticals
MT Newswires · 08/17 16:32
3 Generic Drug Stocks to Watch Amid Pandemic & Pricing Pressure
Zacks.com · 08/17 15:04
Webull provides a variety of real-time AMPH stock news. You can receive the latest news about Amphastar Pharms through multiple platforms. This information may help you make smarter investment decisions.
About AMPH
Amphastar Pharmaceuticals, Inc. is a bio-pharmaceutical company. The Company is primarily focused on developing, manufacturing, marketing and selling generic and injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API, products. It manufactures and sells over 20 products. It operates through two segments: finished pharmaceutical products and API products. It marketed products include Primatene Mist, Enoxaparin, Glucagon for Injection Emergency Kit, Naloxone and Other finished pharmaceutical products. Primatene Mist, an over-the-counter epinephrine inhalation product, is indicated for the temporary relief of mild symptoms of intermittent asthma. Enoxaparin is an injectable form of low molecular weight heparin that is used as an anticoagulant, which is indicated for multiple indications, including the prevention and treatment of deep vein thrombosis. Glucagon for injection is a difficult to manufacture injectable product.